Eventide Asset Management’s Neurogene NGNE Stock Holding History

Eventide Asset Management’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-8,750	Closed	-$2.46M	–	146
2018 Q1	$2.46M	Hold	8,750	–	–	0.12%	106
2017 Q4	$2.06M	Hold	8,750	–	–	0.11%	107
2017 Q3	$2.48M	Hold	8,750	–	–	0.14%	97
2017 Q2	$2.46M	Hold	8,750	–	–	0.15%	91
2017 Q1	$2.92M	Hold	8,750	–	–	0.19%	87
2016 Q4	$2.89M	Buy	+8,750	New	+$2.35M	0.19%	86

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

DAM

DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

UONDDL

University of Notre Dame du Lac South Bend, Indiana $66.8M AUM 43.52% 1-Year Est. Return

Eventide Asset Management's NGNE Position: Q2 2018 in Review

Eventide Asset Management sold out of Neurogene (NGNE) in Q2 2018, closing a stake of 8,750 shares — an estimated $2.46M sold.

Eventide Asset Management first reported a position in NGNE in Q4 2016 and held it in 6 quarters. The position peaked at $2.92M in Q1 2017. 44 funds tracked by Wall St. Rank hold NGNE as of Q2 2018.

Eventide Asset Management reported no remaining Neurogene position as of Q2 2018 after selling out during the quarter.
Eventide Asset Management sold 8,750 Neurogene shares in Q2 2018, an estimated $2.46M.
Eventide Asset Management first reported a position in Neurogene in Q4 2016 and held it in 6 quarters.
Eventide Asset Management's Neurogene position peaked at $2.92M in Q1 2017.
44 funds tracked by Wall St. Rank held Neurogene as of Q2 2018.

Based on Eventide Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.